Novavax, Inc (NVAX) concluded trading on Wednesday at a closing price of $6.92, with 7.88 million shares of worth about $54.5 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -13.93% during that period and on Wednesday the price saw a loss of about -6.23%. Currently the company’s common shares owned by public are about 161.96M shares, out of which, 147.60M shares are available for trading.
Stock saw a price change of -9.90% in past 5 days and over the past one month there was a price change of 3.21%. Year-to-date (YTD), NVAX shares are showing a performance of -13.93% which decreased to -54.32% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.01 but also hit the highest price of $23.86 during that period. The average intraday trading volume for Novavax, Inc shares is 8.35 million. The stock is currently trading 3.83% above its 20-day simple moving average (SMA20), while that difference is up 3.56% for SMA50 and it goes to -23.92% lower than SMA200. Novavax, Inc (NASDAQ: NVAX) currently have 161.96M outstanding shares and institutions hold larger chunk of about 56.77% of that.
The stock has a current market capitalization of $1.12B and its 3Y-monthly beta is at 2.81. PE ratio of stock for trailing 12 months is 2.61, while it has posted earnings per share of $2.65 in the same period. Its PEG reads 0.04 and has Quick Ratio of 2.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVAX, volatility over the week remained 4.05% while standing at 6.19% over the month.
Stock’s fiscal year EPS is expected to rise by 269.54% while it is estimated to decrease by -82.91% in next year. EPS is likely to grow at an annualized rate of 67.93% for next 5-years, compared to annual growth of 25.88% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on February 28, 2025 offering a Buy rating for the stock and assigned a target price of $19 to it. Coverage by JP Morgan stated Novavax, Inc (NVAX) stock as an Underweight in their note to investors on July 30, 2024, suggesting a price target of $8 for the stock. On May 10, 2024, JP Morgan Upgrade their recommendations, while on May 10, 2024, BofA Securities Upgrade their ratings for the stock with a price target of $12. Stock get a Buy rating from B. Riley Securities on August 09, 2023.
